These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

835 related items for PubMed ID: 15243126

  • 21. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
    Zhang G, Cai X, López-Guisa JM, Collins SJ, Eddy AA.
    J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
    [Abstract] [Full Text] [Related]

  • 22. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
    Nishida Y, Hayashi Y, Imai Y, Itoh H.
    Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
    [Abstract] [Full Text] [Related]

  • 23. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M.
    Cancer Res; 1994 Oct 15; 54(20):5445-54. PubMed ID: 7923178
    [Abstract] [Full Text] [Related]

  • 24. Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies.
    Floridon C, Nielsen O, Holund B, Sunde L, Westergaard JG, Thomsen SG, Teisner B.
    Placenta; 1999 Nov 15; 20(8):711-21. PubMed ID: 10527826
    [Abstract] [Full Text] [Related]

  • 25. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
    Kumamoto H, Ooya K.
    J Oral Pathol Med; 2007 Sep 15; 36(8):488-94. PubMed ID: 17686008
    [Abstract] [Full Text] [Related]

  • 26. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
    Del Rosso A, Cinelli M, Guiducci S, Pignone A, Fibbi G, Margheri F, Gabrielli A, Giacomelli R, Coppini A, Del Rosso M, Matucci Cerinic M.
    Rheumatology (Oxford); 2005 Oct 15; 44(10):1255-62. PubMed ID: 15998634
    [Abstract] [Full Text] [Related]

  • 27. The urokinase plasminogen activator (uPA) system in uterine natural killer cells in the placental bed during early pregnancy.
    Naruse K, Lash GE, Bulmer JN, Innes BA, Otun HA, Searle RF, Robson SC.
    Placenta; 2009 May 15; 30(5):398-404. PubMed ID: 19272641
    [Abstract] [Full Text] [Related]

  • 28. [Plasminogen activators and plasminogen activator inhibitor type-1 in human endometrium].
    Chen GA, Feng Q, Zhang LZ, Liu YX.
    Sheng Li Xue Bao; 1992 Oct 15; 44(5):502-9. PubMed ID: 1293766
    [Abstract] [Full Text] [Related]

  • 29. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium.
    Papp C, Schatz F, Krikun G, Hausknecht V, Lockwood CJ.
    Early Pregnancy (Cherry Hill); 2000 Oct 15; 4(4):230-9. PubMed ID: 11742418
    [Abstract] [Full Text] [Related]

  • 30. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R, Landete JM, España F, Vázquez C, Fuster C, Almenar SM, Ramón LA, Radtke KP, Estellés A.
    Thromb Res; 2007 Oct 15; 120(5):753-62. PubMed ID: 17258797
    [Abstract] [Full Text] [Related]

  • 31. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD, Tomaso H, Mengele K, Schilling D, Bayer C, Stadler P, Schmitt M, Molls M.
    Oncol Rep; 2007 May 15; 17(5):1259-68. PubMed ID: 17390074
    [Abstract] [Full Text] [Related]

  • 32. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM, Strickland S.
    J Cell Physiol; 1997 May 15; 171(2):217-25. PubMed ID: 9130470
    [Abstract] [Full Text] [Related]

  • 33. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T, Behrendt N, Ploug M.
    Stem Cells; 1997 May 15; 15(6):398-408. PubMed ID: 9402652
    [Abstract] [Full Text] [Related]

  • 34. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C, Yu J, Huang S.
    Mol Carcinog; 2007 Mar 15; 46(3):165-75. PubMed ID: 17186542
    [Abstract] [Full Text] [Related]

  • 35. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V.
    Int J Mol Med; 2008 Feb 15; 21(2):251-9. PubMed ID: 18204793
    [Abstract] [Full Text] [Related]

  • 36. Expression of urokinase-type plasminogen activator and its receptor is up-regulated during tendon healing.
    Xia W, de Bock C, Murrell GA, Wang Y.
    J Orthop Res; 2003 Sep 15; 21(5):819-25. PubMed ID: 12919869
    [Abstract] [Full Text] [Related]

  • 37. In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas.
    Sordat I, Chaubert P, Protiva P, Guillou L, Mazzucchelli L, Saraga E, Benhattar J, Trân-Thang C, Blum AL, Dorta G, Sordat B.
    Am J Pathol; 1997 Jan 15; 150(1):283-95. PubMed ID: 9006343
    [Abstract] [Full Text] [Related]

  • 38. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
    Türkmen B, Schmitt M, Schmalfeldt B, Trommler P, Hell W, Creutzburg S, Graeff H, Magdolen V.
    Electrophoresis; 1997 May 15; 18(5):686-9. PubMed ID: 9194591
    [Abstract] [Full Text] [Related]

  • 39. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H.
    Biol Chem; 2001 Aug 15; 382(8):1197-205. PubMed ID: 11592401
    [Abstract] [Full Text] [Related]

  • 40. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 15; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.